The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Abevmy bevacizumab Biosimilar | Biosimilar Collaborations Ireland Limited | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2021-04-21 | Order → |
| Jemperli dostarlimab Additional monitoring | GlaxoSmithKline Trading Services Limited | Endometrial Neoplasms | 🇪🇺 EU 2021-04-21 | Order → |
| Sogroya somapacitan Additional monitoring | Novo Nordisk A/S | Growth | 🇪🇺 EU 2021-03-31 | Order → |
| Alymsys bevacizumab Biosimilar | Mabxience Research SL | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplas | 🇪🇺 EU 2021-03-26 | Order → |
| BroPair Spiromax salmeterol;fluticasone propionate | Teva B.V. | Asthma | 🇪🇺 EU 2021-03-26 | Order → |
| Byfavo remimazolam | Paion Pharma GmbH | Conscious Sedation | 🇪🇺 EU 2021-03-26 | Order → |
| Evrysdi risdiplam PRIMEAccelerated assessment | Roche Registration GmbH | Muscular Atrophy, Spinal | 🇪🇺 EU 2021-03-26 | Order → |
| Kesimpta ofatumumab | Novartis Europharm Limited | Multiple Sclerosis, Relapsing-Remitting | 🇪🇺 EU 2021-03-26 | Order → |
| Nexpovio selinexor Additional monitoring | Stemline Therapeutics B.V. | Multiple Myeloma | 🇪🇺 EU 2021-03-26 | Order → |
| Ontozry cenobamate Additional monitoring | Angelini Pharma S.p.A | Epilepsy | 🇪🇺 EU 2021-03-26 | Order → |
| Oyavas bevacizumab Biosimilar | STADA Arzneimittel AG | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2021-03-26 | Order → |
| Pemazyre pemigatinib OrphanConditionalAdditional monitoring | Incyte Biosciences Distribution B.V. | Cholangiocarcinoma | 🇪🇺 EU 2021-03-26 | Order → |
| Seffalair Spiromax salmeterol;fluticasone propionate | Teva B.V. | Asthma | 🇪🇺 EU 2021-03-26 | Order → |
| Thiotepa Riemser thiotepa Generic | Esteve Pharmaceuticals GmbH | Hematopoietic Stem Cell Transplantation; Neoplasms | 🇪🇺 EU 2021-03-26 | Order → |
| Vazkepa icosapent ethyl Additional monitoring | Recordati Industria Chimica e Farmaceutica S.p.A. | Dyslipidemias | 🇪🇺 EU 2021-03-26 | Order → |
| Jcovden (previously COVID-19 Vaccine Janssen) COVID-19 vaccine (Ad26.COV2-S [recombinant]) Additional monitoring | Janssen-Cilag International NV | COVID-19 virus infection | 🇪🇺 EU 2021-03-11 | Order → |
| Heplisav B hepatitis B surface antigen | Dynavax GmbH | Hepatitis B | 🇪🇺 EU 2021-02-18 | Order → |
| Lenalidomide Krka d.d. lenalidomide Generic | KRKA tovarna zdravil d.d. Novo mesto | Multiple Myeloma; Lymphoma, Follicular; Myelodysplastic Syndromes | 🇪🇺 EU 2021-02-11 | Order → |
| Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) lenalidomide Generic | KRKA tovarna zdravil d.d. Novo mesto | Multiple Myeloma; Lymphoma, Follicular | 🇪🇺 EU 2021-02-11 | Order → |
| Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) lenalidomide Generic | KRKA tovarna zdravil d.d. Novo mesto | Multiple Myeloma; Myelodysplastic Syndromes; Lymphoma, Follicular; Lymphoma, Mantle-Cell | 🇪🇺 EU 2021-02-11 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.